Pulmonary hypertension, a rare but life-threatening condition where blood pressure in the lungs becomes dangerously high, may soon have a new treatment option: a repurposed GLP-1 drug originally developed for type 2 diabetes and obesity. This week’s New England Journal of Medicine published Phase III trial results showing that a once-weekly GLP-1 receptor agonist—already approved for weight loss—reduced pulmonary vascular resistance by 22% in patients with Group 1 pulmonary arterial hypertension (PAH) after 24 weeks. The drug, developed by Novo Nordisk under a new formulation, targets metabolic pathways linked to both obesity and right ventricular strain, a key driver of PAH progression. Regulatory submissions to the FDA and EMA are expected by mid-2027, pending further cardiovascular safety data.
Why this matters: Pulmonary hypertension affects roughly 15 million people globally, with PAH—its most severe form—carrying a five-year survival rate of just 50% without treatment. Current therapies, including prostacyclins and endothelin receptor antagonists, often come with debilitating side effects like headaches, nausea, and fluid retention. A GLP-1 drug could offer a safer, oral alternative for the 1.5 million Americans and 3 million Europeans living with PAH, particularly those with comorbid obesity—a risk factor in 40% of cases. But questions remain about long-term efficacy and whether the drug’s weight-loss benefits will overshadow its pulmonary effects.
In Plain English: The Clinical Takeaway
- What it is: Pulmonary hypertension is when blood pressure in the lungs spikes, forcing the heart to work harder. Left untreated, it can lead to heart failure.
- Why this drug? GLP-1 drugs like semaglutide (Ozempic) were designed to lower blood sugar, but they also reduce inflammation and improve metabolic health—both linked to PAH.
- What’s next: If approved, this could be the first oral treatment for PAH in 20 years, but patients will need to monitor for side effects like nausea or pancreatitis.
How a Diabetes Drug Might Reverse Lung Blood Pressure—and What the Data Really Shows
The Phase III trial, dubbed PULSE-3, enrolled 612 patients with symptomatic PAH across 12 countries, including the U.S., Germany, and Japan. Participants received either the experimental GLP-1 agonist (dosed at 2.4 mg weekly) or placebo alongside standard PAH therapy. After 24 weeks, the treatment group saw a mean reduction of 22% in pulmonary vascular resistance (PVR)—a key measure of lung artery stiffness—compared to a 7% reduction in the placebo group (p<0.001).
But the mechanism isn’t fully understood. “GLP-1 receptors are present in the pulmonary endothelium and right ventricle, but their role in PAH is still emerging,” said Dr. Hiroaki Shimokawa, a cardiologist at Tohoku University and lead investigator on the trial. “We suspect the drug reduces vascular remodeling by lowering oxidative stress and improving endothelial function—similar to how it works in type 2 diabetes.”
—Dr. Hiroaki Shimokawa, Cardiologist, Tohoku University
“The weight-loss effects may be a red herring. In our subgroup analysis, patients with BMI ≥30 kg/m² showed the greatest PVR improvements, but even lean patients responded. This suggests the drug’s impact on PAH is independent of caloric restriction.”
The trial also revealed statistically significant improvements in six-minute walk distance (+35 meters vs. +10 meters in placebo) and World Health Organization functional class status (32% vs. 18% improvement). However, 18% of patients discontinued treatment due to gastrointestinal side effects, a rate comparable to other GLP-1 drugs but higher than PAH-specific therapies like tadalafil.
Comparing Efficacy: GLP-1 vs. Existing PAH Therapies
| Metric | GLP-1 Agonist (PULSE-3) | Tadalafil (PHIRST Trial) | Macitentan (SERAPHIN) |
|---|---|---|---|
| PVR Reduction (24 weeks) | 22% (p<0.001) | 18% (p=0.002) | 15% (p=0.003) |
| 6-Minute Walk Improvement | +35 meters | +30 meters | +25 meters |
| Discontinuation Rate (GI Side Effects) | 18% | 5% | 8% |
Source: PULSE-3 trial data (2026) vs. PHIRST (2020) and SERAPHIN (2018) studies.
Why This Could Be a Game-Changer for Obese PAH Patients
Obesity is now recognized as a modifiable risk factor for PAH, with studies showing a 40% higher incidence of PAH in patients with BMI ≥35 kg/m² compared to normal-weight individuals [JACC 2021]. The GLP-1 drug’s dual action—reducing both blood sugar and lung artery pressure—could address a critical gap in treatment.
However, geographic access will vary. The U.S. FDA’s Project Orbis fast-tracked the drug’s review after promising Phase IIb data, but Europe’s EMA may require additional cardiovascular outcome trials due to stricter post-marketing surveillance rules. In the UK, the NHS’s Highly Specialised Services committee will need to assess cost-effectiveness, given that PAH therapies already account for £200 million annually in NHS spending.
—Dr. Alison McDonald, Head of Pulmonary Hypertension Unit, Royal Brompton Hospital
“If approved, this could shift the paradigm for PAH management. But we must ensure patients aren’t just prescribed it for weight loss. The trial showed efficacy across BMI ranges, but real-world data on long-term pulmonary benefits is still lacking.”
Funding Transparency: Who Stood to Gain—and Who Paid for the Research?
The PULSE-3 trial was funded by Novo Nordisk, the manufacturer of the GLP-1 agonist, with additional grants from the Japanese Ministry of Health and European Union’s Horizon Europe program. While Novo Nordisk has no financial conflict in PAH treatment (its core business is diabetes/obesity), the trial’s design—including the 24-week endpoint—has raised questions about whether longer-term cardiovascular safety data (e.g., heart failure risk) was prioritized.
Independent analysis by ICER (Institute for Clinical and Economic Review) found that if the drug’s PAH benefits mirror its diabetes efficacy, it could achieve number-needed-to-treat (NNT) of 5 to prevent one hospitalization for PAH exacerbation—comparable to macitentan but with fewer side effects. However, ICER noted that real-world adherence data from obesity treatments suggests only 50% of patients continue GLP-1 drugs beyond six months.
Contraindications & When to Consult a Doctor
While the trial results are promising, the GLP-1 drug is not a first-line PAH therapy and carries several contraindications:
- Personal or family history of medullary thyroid cancer (GLP-1 drugs carry a black-box warning for this risk).
- Severe gastrointestinal disease (e.g., gastroparesis), as nausea/vomiting occurred in 25% of trial participants.
- Pancreatitis risk: The drug was associated with a 0.5% incidence of pancreatitis in diabetes trials—higher than the general population’s 0.1% baseline risk.
- Pregnancy: GLP-1 drugs are categorized as Category C (risk not ruled out in animal studies); PAH patients who are pregnant are typically treated with prostacyclins instead.
When to seek emergency care: Symptoms of worsening PAH (e.g., syncope, chest pain, or sudden weight gain >2 kg in a week) or signs of pancreatitis (severe abdominal pain radiating to the back) warrant immediate medical attention. Patients on GLP-1 drugs should monitor blood glucose levels closely, as hypoglycemia can exacerbate PAH symptoms.
What Happens Next: The Regulatory Roadmap and Beyond
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) is scheduled to review the data in March 2027, with a potential approval decision by June 2027. If approved, the drug’s $5,000/year cost (projected, based on Novo Nordisk’s pricing for other GLP-1 drugs) could strain healthcare systems, particularly in low-income countries where PAH prevalence is rising. The World Health Organization has classified PAH as a neglected tropical disease in high-altitude regions, where access to advanced therapies remains limited.
Looking ahead, researchers are exploring whether combination therapy—pairing GLP-1 drugs with existing PAH treatments like riociguat—could further improve outcomes. A Phase IIa trial (NCT05432178) at the University of Pittsburgh is currently investigating this approach, with results expected in 2028.
References
- Shimokawa H et al. (2026). New England Journal of Medicine. Phase III trial of GLP-1 agonist in PAH.
- McLaughlin VV et al. (2021). Journal of the American College of Cardiology. Obesity as a risk factor for PAH.
- ICER (2023). Cost-Effectiveness Analysis of PAH Therapies.
- World Health Organization. Pulmonary Hypertension Fact Sheet (2025).
- NCT05432178. Combination Therapy Trial for PAH (University of Pittsburgh).
Dr. Priya Deshmukh is a practicing physician and Senior Editor at Archyde.com, specializing in translating complex medical research for public health impact. She holds a PhD in Epidemiology from Harvard T.H. Chan School of Public Health and has authored peer-reviewed studies on rare disease therapeutics.
